Cover Image

A successful switch from guselkumab to tildrakizumab during the treatment of a patient with psoriasis vulgaris

Saved in:

Bibliographic Details
Main Authors:	Kazuki Yatsuzuka (Author), Masamoto Murakami (Author)
Format:	Book
Published:	Frontiers Media S.A., 2023-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
by: Ruggiero A, et al.
Published: (2022)

Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis
by: Cathrine Dawn Büttner Elgaard, et al.
Published: (2023)

Successful treatment of generalized pustular psoriasis with guselkumab
by: Martina Part
Published: (2024)

Tildrakizumab in Psoriasis and Beyond
by: Aditya K. Bubna, et al.
Published: (2024)

A Case of Concurrent Psoriasis and Hidradenitis Suppurativa Successfully Treated with Tildrakizumab
by: Thomas Damsin
Published: (2023)

Effectiveness and Safety After a Switch to Tildrakizumab: A Real World Multicenter Italian Study in Psoriasis
by: Eugenia Veronica Di Brizzi, et al.
Published: (2023)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data
by: Martora F, et al.
Published: (2023)

Guselkumab for the treatment of psoriasis - evidence to date
by: Miguel Nogueira, et al.
Published: (2019)

A 3-Year Multicentric Study on Switching from Ustekinumab to Guselkumab in Partial Responders with Psoriasis-IL PSO (Italian Landscape Psoriasis)
by: Mario Valenti, et al.
Published: (2024)

Guselkumab - In Psoriasis and Beyond
by: Aditya Kumar Bubna, et al.
Published: (2024)

Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy
by: Deeti J. Pithadia, et al.
Published: (2019)

Plantar pustules in a psoriasis patient during the guselkumab therapy
by: Shinsuke Nakazawa, et al.
Published: (2021)

Multirefractory bullous pemphigoid, psoriasis and psoriatic arthritis successfully treated with guselkumab
by: Francisco José Rodríguez-Cuadrado, et al.
Published: (2024)

Treatment of moderate‐to‐severe plaque psoriasis with tildrakizumab in the real‐life setting
by: Alessio Gambardella, et al.
Published: (2023)

Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting
by: Martina Burlando, et al.
Published: (2021)

Tildrakizumab Treatment for Psoriasis in Real-world Practice: An Analysis from the Swiss Registry (SDNTT)
by: Julia-Tatjana Maul, et al.
Published: (2024)

A 3-Year Experience with Tildrakizumab Treatment for Patients with Plaque Psoriasis in Clinical Practice
by: Martina Burlando, et al.
Published: (2024)

Successful long‐term guselkumab treatment of severe plaque psoriasis in patients with class III obesity: A case series
by: Marco Galluzzo, et al.
Published: (2024)

A case of concomitant hidradenitis suppurativa and psoriasis successfully treated with guselkumab in a patient with Down syndrome
by: Simge Ünal, et al.
Published: (2024)

Tildrakizumab: Successful Response in Two Patients with Psoriatic Arthritis
by: Dario Buononato, et al.
Published: (2022)

Seven cancer patients receiving Guselkumab for treatment of moderate-to-severe psoriasis
by: Luca Mastorino, et al.
Published: (2022)

Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
by: Light JG, et al.
Published: (2021)

Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date
by: Beck KM, et al.
Published: (2018)

Guselkumab for the treatment of severe plaque psoriasis in a schizophrenia patient: a case report
by: Nicoletta Bernardini, et al.
Published: (2022)

Can Biologic Agents Improve Treatment Success in Obese Patients With Psoriasis Vulgaris: A Retrospective Review of 320 Patients With Psoriasis Vulgaris
by: Atıl Avcı, et al.
Published: (2024)

Erythrodermic psoriasis treatment with Guselkumab: report of two cases and literature review
by: Esperanza Welsh, et al.
Published: (2024)

Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis
by: Yang EJ, et al.
Published: (2019)

Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study
by: Ruggiero A, et al.
Published: (2023)

Successful treatment of severe psoriasis vulgaris in child with methotrexate injection
by: Agatha Anindhita, et al.
Published: (2019)

Long term efficacy, safety and tolerability of Tildrakizumab in epileptic patient with psoriasis and eczema
by: Nicoletta Bernardini, et al.
Published: (2022)

Rapid Remission of Sunburn-Induced Guttate Psoriasis with Guselkumab
by: Erin Bartholomew, et al.
Published: (2023)

Patients with Persistent Mild Psoriasis after Treatment with Ustekinumab Achieved Greater Improvements in Skin Clearance and Patient-reported Outcomes after Switching to Guselkumab in the Phase 3 NAVIGATE Trial
by: Enzo Errichetti, et al.
Published: (2024)

Clinically and radiologically successful treatment of spondylitis by guselkumab in a patient with pustulotic arthro‐osteitis
by: Natsumi Ikumi, et al.
Published: (2023)

Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis
by: Tarja Mälkönen, et al.
Published: (2022)

Tildrakizumab in the treatment of plaque psoriasis in an HIV+ patient: a case report and literature review of anti-interleukin drugs
by: Viviana Lora, et al.
Published: (2024)

Targeting p19 as a treatment option for psoriasis: an evidence-based review of guselkumab
by: Wechter T, et al.
Published: (2018)

Tildrakizumab for the treatment of moderate-to-severe psoriasis: a 52-week, real-world Portuguese multicentric study
by: Tiago Torres, et al.
Published: (2024)

Clinical observation of guselkumab in the treatment of 23 cases of moderate to severe plaque psoriasis
by: Liye XIA, et al.
Published: (2024)

Transcription Factor IRF7 is Involved in Psoriasis Development and Response to Guselkumab Treatment
by: Yuan X, et al.
Published: (2024)

Tildrakizumab: An Evidence-Based Review of Its Use in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis
by: Näslund-Koch C, et al.
Published: (2020)